NV
NVCR.US Novocure Ltd
- Market cap
- USD 1.38B
- P/E
- -
- P/B
- 3.94x
- ROE
- -37.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NVCR.US undervalued?
Graham numberThe Graham number of Novocure Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novocure Ltd fundamental analysis
No fundamental analysis for Novocure Ltd yet.
Novocure Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-smal…
Full company profileNovocure Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novocure Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 82.9M | 177M | 248M | 351M | 494M | 535M | 538M | 509M | 605M | 655M | 735M |
| Gross Profit | 36.6M | 121M | 168M | 263M | 388M | 420M | 423M | 381M | 468M | 488M | 569M |
| Operating Income | -115M | -39.3M | -33.7M | -914K | 30.4M | -44.3M | -89.5M | -233M | -170M | -154M | -112M |
| EBITDA | -110M | -31.7M | -24.7M | 7.55M | 44.8M | -34.1M | -78.9M | -177M | -110M | -122M | -90.0M |
| Net Income | -132M | -61.7M | -63.6M | -7.23M | 19.8M | -58.4M | -92.5M | -207M | -169M | -136M | -130M |
| EPS | -1.54 | -0.70 | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 | -1.11 |
| Balance Sheet | |||||||||||
| Total Assets | 282M | 265M | 340M | 479M | 1.05B | 1.14B | 1.19B | 1.15B | 1.24B | 804M | 829M |
| Total Liabilities | 140M | 152M | 228M | 262M | 575M | 729M | 750M | 784M | 881M | 464M | 478M |
| Shareholders' Equity | 142M | 114M | 112M | 218M | 477M | 410M | 441M | 362M | 360M | 340M | 351M |
| Cash & Short-term Investments | 220M | 183M | 246M | 326M | 854M | 938M | 969M | 911M | 960M | 458M | 463M |
| Total Debt | 193M | 195M | 149M | 187M | 451M | 632M | 639M | 596M | 683M | 290M | 232M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -108M | -33.1M | -1.87M | 26.6M | 99.1M | 82.8M | 30.8M | -73.3M | -26.4M | -49.0M | 28.8M |
| Capital Expenditure | 17.7M | 7.37M | 6.71M | 10.5M | 15.0M | 24.2M | 21.4M | 27.1M | 42.9M | 26.6M | 25.3M |
| Free Cash Flow | -125M | -40.5M | -8.58M | 16.1M | 84.2M | 58.6M | 9.43M | -100M | -69.2M | -75.7M | 3.47M |
| Ratios | |||||||||||
| ROE | -92.6% | -54.3% | -56.6% | -3.3% | 4.2% | -14.2% | -21.0% | -57.1% | -46.8% | -40.0% | -37.0% |
| ROA | -46.7% | -23.2% | -18.7% | -1.5% | 1.9% | -5.1% | -7.8% | -18.1% | -13.6% | -16.9% | -15.6% |
| Net Profit Margin | -159.1% | -34.8% | -25.6% | -2.1% | 4.0% | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% | -17.6% |
| Debt to Equity | 1.35x | 1.72x | 1.33x | 0.86x | 0.95x | 1.54x | 1.45x | 1.64x | 1.90x | 0.85x | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novocure Ltd dividends
Novocure Ltd has not paid dividends in the last 9 fiscal years.
Who owns Novocure Ltd
- Insiders 10.00%
- Institutions 89.62%
- Public & others 0.38%
- Shares outstanding 117M
- Free float 97.4M
Top funds holding NVCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 5.87M | 5.02% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.51M | 3.00% | +0.38% | Sep 2026 |
| iShares Russell 2000 ETF | 2.72M | 2.32% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 2.49M | 2.13% | -1.52% | Sep 2026 |
| Fidelity Growth Company K6 | 1.74M | 1.49% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 1.55M | 1.33% | 0.00% | Aug 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.39M | 1.19% | -4.31% | Sep 2026 |
| Fidelity Small Cap Index | 1.17M | 1.00% | +0.16% | Aug 2026 |
| C WorldWide Healthcare Select 1A | 972K | 0.83% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 933K | 0.80% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 816K | 0.70% | -0.19% | Oct 2026 |
| Vanguard Strategic Equity Inv | 686K | 0.59% | +57.55% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 627K | 0.54% | +1.62% | Sep 2026 |
| Vanguard Russell 2000 ETF | 622K | 0.53% | +1.14% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 567K | 0.49% | +0.24% | Oct 2026 |
| iShares US Medical Devices ETF | 511K | 0.44% | -1.12% | Oct 2026 |
| Fidelity Extended Market Index | 496K | 0.42% | -3.99% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 494K | 0.42% | +141.16% | Aug 2026 |
| BlackRock Advantage Small Cap Core Instl | 447K | 0.38% | -3.32% | Sep 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 431K | 0.37% | +0.43% | Oct 2026 |
Top institutions holding NVCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 17.4M | 14.86% | +1.78% | Jun 2026 |
| BlackRock Inc | 13.4M | 11.47% | +1.67% | Jun 2026 |
| Soleus Capital Management, L.P. | 9.91M | 8.48% | -5.52% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.27M | 5.37% | +0.33% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.90M | 4.19% | +4.73% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.52M | 3.87% | -0.42% | Jun 2026 |
| State Street Corp | 2.87M | 2.45% | +11.90% | Jun 2026 |
| Geode Capital Management, LLC | 2.80M | 2.39% | +11.41% | Jun 2026 |
| Wells Fargo & Co | 2.53M | 2.16% | -14.34% | Jun 2026 |
| Quantinno Capital Management LP | 2.22M | 1.90% | -10.61% | Jun 2026 |
| Renaissance Technologies Corp | 2.12M | 1.81% | +8.49% | Sep 2026 |
| JPMorgan Chase & Co | 1.67M | 1.43% | +79.65% | Jun 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.39M | 1.19% | +90.75% | Jun 2026 |
| Palo Alto Investors, LLC | 1.28M | 1.10% | 0.00% | Jun 2026 |
| Nuveen, LLC | 1.23M | 1.05% | +25.42% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.16M | 1.00% | -12.57% | Jun 2026 |
| Empowered Funds, LLC | 1.15M | 0.99% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 1.10M | 0.94% | +300.87% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.08M | 0.93% | -0.79% | Sep 2026 |
| D. E. Shaw & Co LP | 1.02M | 0.87% | +58.02% | Jun 2026 |
Novocure Ltd company profile
- Company name
- Novocure Ltd
- Ticker
- NVCR.US
- ISIN
- JE00BYSS4X48
- Exchange
- USA Stocks
- Listed since
- Oct 2, 2015
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,605
- Fiscal year end
- December
- Address
- Neuhofstrasse 21, Baar, Switzerland, 6340
- Phone
- 44 15 3475 6700
- Website
- novocure.com
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Novocure Ltd management
8- Mr. William F. DoyleExecutive Chairman · born 1962
- Mr. Frank LeonardCEO & Director
- Mr. Christoph BrackmannChief Financial Officer · born 1974
- Mr. Michael PuriChief Human Resources Officer · born 1969
- Dr. Uri Weinberg M.D., Ph.D.Chief Innovation Officer & Chief Medical Officer · born 1978
- Mr. Mukund ParavasthuChief Operating Officer · born 1970
- Mr. Adam DaneyHead of Investor Relations
- Mr. Barak Ben-AryeGeneral Counsel · born 1977